Zhejiang Tianyu Pharmaceutical Co., Ltd.

Equities

300702

CNE1000034X1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 15/05/2024 am IST 5-day change 1st Jan Change
20.85 CNY +0.10% Intraday chart for Zhejiang Tianyu Pharmaceutical Co., Ltd. +3.68% -3.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Approves Tianyu Pharma's Heart Medication MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024. CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection MT
Tianyu Pharma Unit Passes US FDA On-Site Inspection MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 30, 2022, has expired with 2,403,643 shares, representing 0.69% for CNY 58 million. CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component A Share Index CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component Index CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022. CI
Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.
More charts
Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The Company also operates Other segment. The Company sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.85 CNY
Average target price
22.6 CNY
Spread / Average Target
+8.39%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300702 Stock
  4. News Zhejiang Tianyu Pharmaceutical Co., Ltd.
  5. Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW